Table 1.

NOPR cohort clinical characteristics

	Cancer Type
	All	Bladder	Kidney	Ovary	Pancreas	Prostate	SCL*	Stomach
Patients, n	8,460	1,127	1,070	2,075	862	1,974	720	632
Age, mean in years	74.1	75.2	73.7	73.1	74.1	75.3	72.8	74.6
(25–75% range)	69–79	70–80	39–78	68–77	69–79	70–80	68–77	69–79
ECOG performance status
Asymptomatic (0), %	42.6	34.3	43.2	50.5	34.7	51.5	23.0	36.6
Fully ambulatory (1), %	46.1	51.5	43.7	43.0	50.8	38.8	59.5	49.6
P.S. 2, 3, or 4, %	11.3	14.2	13.0	6.5	14.5	9.7	17.5	13.8
Post-PET summary stage (%)
No evidence of disease or low probability of local recurrence	43.0	42.1	45.8	36.9	40.3	48.1	40.1	51.4
Local or nodal disease	13.5	14.6	8.3	11.1	17.6	15.1	17.4	13.0
Metastatic disease	43.5	43.3	45.9	52.0	42.1	36.8	42.5	35.6
Comorbidity score, %
0	47.9	37.1	38.5	66.3	39.2	52.4	26.7	44.8
1 or 2	38.4	40.1	37.1	29.0	49.0	35.6	56.7	42.2
≥3	13.7	22.8	24.4	4.7	11.8	12.0	16.7	13.0
Referring M.D. specialty, %
Medical oncology*	50.6	60.0	51.0	42.8	61.9	37.7	68.8	63.3
Radiation oncology	8.8	7.4	5.6	1.9	6.8	19.2	11.5	6.2
Internal medicine†	8.0	7.5	12.7	5.1	7.9	9.1	8.5	7.3
Urology	6.2	8.9	10.7	--	--	15.5	0.0	--
Gynecology/Gynecologic Oncology	9.0	0.4	0.5	35.7	--	--	0.6	--
Surgery	3.5	1.3	4.4	2.3	8.8	1.8	1.8	9.3
Other	13.9	14.5	15.1	12.1	14.5	16.7	8.9	13.9
30 days post-PET, %
Hospitalized	11.5	16.0	12.7	11.5	13.1	7.5	11.2	12.5
Death	1.6	3.6	1.5	0.4	2.1	1.0	3.6	1.6
Pre-PET Plan, %
Watching	11.7	10.3	9.8	10.4	12.8	12.5	11.7	13.9
Additional imaging	49.8	48.2	47.8	52.9	50.5	45.2	50.9	52.5
Biopsy	12.4	15.6	21.2	12.5	9.5	11.8	9.6	11.1
Treatment	26.1	25.9	21.2	24.2	27.2	30.4	27.9	22.5

^*SCL: small cell lung

^† Internal medicine: Sum of all internal medicine specialties excluding medical oncology and hematology